Harrow Licenses Canadian Rights To Apotex For Five Branded Ophthalmic Pharmaceutical Products
Portfolio Pulse from Benzinga Newsdesk
Harrow, Inc. (NASDAQ:HROW) has entered into an exclusive out-licensing agreement with Apotex Inc., Canada's largest pharmaceutical company, to market and distribute five branded ophthalmic pharmaceutical products in Canada. The agreement includes the marketing and distribution of VERKAZIA® and Cationorm® PLUS, as well as pursuing market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®. This partnership marks Harrow's entry into the Canadian market, aiming to enhance access and availability of these ophthalmic products to Canadian patients.
February 15, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow, Inc. has signed an exclusive agreement with Apotex for the Canadian rights to five ophthalmic products, aiming to expand its market presence in Canada.
The partnership with Apotex, a leading Canadian pharmaceutical company, for the distribution and potential market approval of five ophthalmic products represents a significant expansion opportunity for Harrow, Inc. into the Canadian market. This strategic move is likely to be viewed positively by investors, as it opens up new revenue streams and enhances the company's product portfolio in a key international market. The focus on ophthalmic products, a specialized area of healthcare, further strengthens Harrow's position in this niche market.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100